Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute leukemia subclassification: a marker protein expression perspective.

Geertruy Te Kronnie1, Silvio Bicciato, Giuseppe Basso

  • 1Department of Pediatrics, University of Padova, Italy. truustekronnie@unipd.it

Hematology (Amsterdam, Netherlands)
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy.

Nature communications·2026
Same author

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.

Blood·2024
Same author

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.

HemaSphere·2023
Same author

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.

Science advances·2022
Same author

FOXA1 regulates alternative splicing in prostate cancer.

Cell reports·2022
Same author

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD).

Cancers·2022
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Quantitative analysis of immunophenotypic marker proteins using flow cytometry can accurately classify acute leukemia (AL) subtypes. This approach aids in distinguishing specific genetic alterations like MLL rearrangements for improved diagnosis and treatment strategies.

Area of Science:

  • Hematology
  • Immunology
  • Bioinformatics

Background:

  • Acute leukemia (AL) classification and therapy tailoring have improved patient outcomes, especially in pediatric cases.
  • Current diagnostic methods like immunophenotyping, molecular genetics, and cytogenetics have been integrated into routine leukemia subclass diagnosis.
  • Future advancements in leukemia classification and understanding its biology are expected to be more challenging.

Purpose of the Study:

  • To explore the classification of acute leukemia samples using flow cytometry and immunophenotypic marker proteins as part of proteomic analysis.
  • To evaluate the potential of quantitative multivariate analysis of marker protein expression profiles for clinical diagnosis.

Main Methods:

  • Marker protein expressions from flow cytometry were converted into quantitative values.

Related Experiment Videos

  • Computational analysis, specifically quantitative multivariate analysis, was applied to these expression values.
  • The study focused on using immunophenotyping data as a component of proteomic analysis.

    • Main Results:

    • Quantitative multivariate analysis of marker protein expression profiles successfully distinguished MLL-rearranged (MLLre) from non-MLLre acute lymphoblastic leukemia (ALL) cases.
    • The analysis also allowed for the specific differentiation of MLL/AF4 cases.
    • These findings suggest the potential utility of quantitative expression analyses in clinical diagnostics.

    Conclusions:

    • Quantitative immunophenotypic data analysis holds promise for improving acute leukemia classification.
    • Flow cytometry is an accessible technology for data collection, and its translation into quantitative datasets is feasible.
    • Validation of quantitative immunophenotypic data set analysis in large, independent datasets is crucial before clinical implementation.